These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32583235)

  • 1. Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
    Kim SH; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):3025-3036. PubMed ID: 32583235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
    Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
    Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
    Grossi F; Genova C; Crinò L; Delmonte A; Turci D; Signorelli D; Passaro A; Soto Parra H; Catino A; Landi L; Gelsomino F; Tiseo M; Puppo G; Roila F; Ricciardi S; Tonini G; Cognetti F; Toschi L; Tassinari D; Scoppola A; Giannarelli D; Cortesi E
    Eur J Cancer; 2019 Dec; 123():72-80. PubMed ID: 31671314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
    Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Hata T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
    J Thorac Oncol; 2019 Mar; 14(3):468-474. PubMed ID: 30468872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis.
    Kobayashi K; Nakachi I; Naoki K; Satomi R; Nakamura M; Inoue T; Tateno H; Sakamaki F; Sayama K; Terashima T; Koh H; Abe T; Nishino M; Arai D; Yasuda H; Kawada I; Soejima K; Betsuyaku T;
    Clin Lung Cancer; 2018 May; 19(3):e349-e358. PubMed ID: 29398578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer.
    Enomoto T; Tamiya A; Matsumoto K; Adachi Y; Azuma K; Inagaki Y; Kouno S; Taniguchi Y; Saijo N; Okishio K; Atagi S
    Clin Transl Oncol; 2021 Mar; 23(3):582-590. PubMed ID: 32661824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
    Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
    Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
    Aarnink A; Fumet JD; Favier L; Truntzer C; Ghiringhelli F
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2699-2707. PubMed ID: 32474752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
    Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
    Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study.
    Karadurmus N; Kaplan MA; Sendur MAN; Urun Y; Demirci U; Karaca SB; Goktas Aydin S; Aykan MB; Bilici A; Sezer A; Yilmaz U; Abali H; Yumuk PF; Degirmencioglu S; Demirkazik A; Paydas S; Mirili C; Turna H; Kargi A; Ozdogan M; Guven DC; Ozguroglu M; Kilickap S
    Curr Med Res Opin; 2024 Jul; 40(7):1171-1178. PubMed ID: 38809230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
    Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
    Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.
    Bouhlel L; Doyen J; Chamorey E; Poudenx M; Ilie M; Gal J; Guigay J; Benzaquen J; Marquette CH; Berthet JP; Mouroux J; Schiappa R; Padovani B; Hofman P; Otto J
    Bull Cancer; 2020 Sep; 107(9):946-958. PubMed ID: 32646604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea.
    Lim SM; Kim SW; Cho BC; Kang JH; Ahn MJ; Kim DW; Kim YC; Lee JS; Lee JS; Lee SY; Park KU; An HJ; Cho EK; Jang TW; Kim BS; Kim JH; Lee SS; Na II; Yoo SS; Lee KH
    Cancer Res Treat; 2020 Oct; 52(4):1112-1119. PubMed ID: 32599984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status.
    Adachi Y; Tamiya A; Taniguchi Y; Enomoto T; Azuma K; Kouno S; Inagaki Y; Saijo N; Okishio K; Atagi S
    Cancer Med; 2020 Feb; 9(4):1383-1391. PubMed ID: 31880861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.
    Ricciuti B; Genova C; Bassanelli M; De Giglio A; Brambilla M; Metro G; Baglivo S; Dal Bello MG; Ceribelli A; Grossi F; Chiari R
    Clin Lung Cancer; 2019 May; 20(3):178-185.e2. PubMed ID: 30910574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab-refractory patients with advanced non-small-cell lung cancer.
    Costantini A; Fallet V; Corny J; Friard S; Chouaid C; Duchemann B; Giroux-Leprieur E; Taillade L; Doucet L; Brosseau S; Wislez M; Tredaniel J; Cadranel J
    Lung Cancer; 2019 Apr; 130():128-134. PubMed ID: 30885333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
    Kitadai R; Okuma Y; Hakozaki T; Hosomi Y
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):777-785. PubMed ID: 31828427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
    Crinò L; Bidoli P; Delmonte A; Grossi F; De Marinis F; Ardizzoni A; Vitiello F; Lo Russo G; Parra HS; Cortesi E; Cappuzzo F; Calabrò L; Tiseo M; Turci D; Gamucci T; Antonelli P; Morabito A; Chella A; Giannarelli D; Galetta D
    Oncologist; 2019 Nov; 24(11):e1165-e1171. PubMed ID: 30996007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.